The FDA's clearance of Solid Biosciences' IND is a significant regulatory milestone that typically leads to increased investor confidence and can drive the stock price up in the short term. The news directly impacts the company's potential future revenues and growth, as it allows them to proceed with clinical trials, which are critical for the development and eventual commercialization of their gene therapy candidate.